-
America received a grade of mediocre on its care for the dying in a new report from the Washington, DC-based organization Last Acts, Means to a Better End. The report, funded by the Robert Wood Johnson Foundation in Princeton, NJ, provides a state-by-state report card on end-of-life (EOL) care.
-
The U.S. Department of Health and Human Services has announced that the U.S. Food and Drug Administration (FDA) has approved a new rapid HIV diagnostic test kit that provides results with 99.6% accuracy in as little as 20 minutes.
-
A new protease inhibitor (PI) called atazanavir was found to actually improve the lipid profile of HIV patients in a 48-week study presented at the 40th Annual Meeting of the Infectious Diseases Society of America (IDSA), held in Chicago.
-
While there are some similarities between HIV and tuberculosis (TB) treatments, its the differences in treatment regimens, duration, and end results that have made HIV clinicians and others somewhat hesitant to use the directly observed treatment (DOT) strategy, which has been so successful in treating TB, with HIV patients.
-
While the exact cause remains to be found, it is no longer a mystery whether certain antiretroviral drugs can lead to metabolic changes associated with heart disease.
-
The Adult AIDS Clinical Trials Group (AACTG) has responded to research showing a link between HIV antiretroviral treatment and meta-bolic disorders with guidelines that offer recommendations for assessing, monitoring, and treating the problem.
-
A study conducted at San Francisco General Hospital suggests a greater incidence rate of severe psychiatric illness resulting from HIV treatment with efavirenz than what has previously been reported.
-
The Food and Drug Administration (FDA) has issued new guidance intended to assist sponsors in the clinical development of drugs for the treatment of HIV infection. Specifically, it addresses the FDAs current thinking regarding designs of clinical trials that use HIV ribonucleic acid (RNA) measurements to support accelerated and traditional approvals of antiretroviral drug products.
-
The 12-month results of CREDO (clopidogrel for the Reduction of Events During Observation) were presented at AHA to coincide with the publication of this important clinical trial in the November 20, 2002, issue of JAMA.
-
After years of legal wrangling, the FDA has approved loratadine (Claritin, Schering-Plough) as an over-the-counter (OTC) product for the treatment of seasonal rhinitis.
